Advanced Accelerator Applications (AAA) is an innovative radiopharmaceutical company that develops, produces and commercializes diagnostic and therapeutic molecular nuclear medicine, or MNM, products.
AAA is at the forefront of developing predictive, preventive and personalized tools and procedures that have the potential to radically transform healthcare. Our path to accomplishing this goal is by merging therapeuti...more >
|Latest News||more >|
Advanced Accelerator Applications Reports 39% Sales Growth for Third Quarter 2017
Advanced Accelerator Applications Announces $3.9 Billion All Cash Proposed Tender Offer by Novartis
Advanced Accelerator Applications Announces European Approval of Lutetium (177Lu) Oxodotreotide (Lutathera®) for Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors
|Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources|